Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Through this new set-up, the company intends to make available, affordable high-quality medical diagnostic imaging equipment across Tier 2, 3, and 4 towns in India
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
He has done his Masters in Pharmacy (M. Pharm) and Post Graduate Diploma in Personnel Management & Industrial Relations
There is also a strong synergy between Jubilant and Greencure with respect to OTC portfolio which can be explored for R&D, online acceleration and offline distribution
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
Subscribe To Our Newsletter & Stay Updated
